Home » Stocks » IRWD

Ironwood Pharmaceuticals, Inc. (IRWD)

Stock Price: $9.57 USD -0.03 (-0.26%)
Updated Mar 2, 2021 3:59 PM EST - Market closed
Market Cap 1.54B
Revenue (ttm) 389.52M
Net Income (ttm) 106.18M
Shares Out 159.43M
EPS (ttm) 0.66
PE Ratio 14.49
Forward PE 8.69
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $9.57
Previous Close $9.59
Change ($) -0.03
Change (%) -0.26%
Day's Open 9.71
Day's Range 9.46 - 9.78
Day's Volume 2,324,144
52-Week Range 7.99 - 12.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 3 days ago

Their recent struggles may soon give way to rising market interest and more lucrative returns.

Other stocks mentioned: CHRS, SUPN
Business Wire - 1 week ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, announced that management will be presenting at the following investor conferences: SVB...

Zacks Investment Research - 1 week ago

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.

Zacks Investment Research - 1 week ago

Ironwood (IRWD) delivered earnings and revenue surprises of 33.33% and 9.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 week ago

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 20.00% over the past year to $0.36, w...

Business Wire - 1 week ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2020 results and recent bu...

Zacks Investment Research - 2 weeks ago

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 3 weeks ago

Ironwood Pharmaceuticals Inc's (NASDAQ: IRWD) chief executive officer, Mark Mallon, will step down, effective March 12, “to pursue another leadership opportunity,” less than two years after he...

Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Mark Mallon plans to step down as chief executive officer and a me...

Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full year 2020 investor update conference call and webcast at 8:30 a....

GuruFocus - 1 month ago

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) has the dubious distinction of owning one of the 10 biggest drug trial flops of 2020, according to FierceBiotech. The Boston-based company's once-pr...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, will provide a corporate overview during a presentation and Q&A session at the 39th Ann...

Zacks Investment Research - 2 months ago

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also...

Zacks Investment Research - 3 months ago

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 3 months ago

Earnings yield can be more illuminating than the traditional P/E ratio as the former facilitates comparison of stocks with fixed-income securities.

Other stocks mentioned: ALLY, MCFT, ODP, REZI
Seeking Alpha - 3 months ago

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in a virtual fireside chat at the 29th Annual Credit Suisse Healthcare Conference on Wednesday, November...

Zacks Investment Research - 3 months ago

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.

Zacks Investment Research - 3 months ago

Ironwood (IRWD) delivered earnings and revenue surprises of 64.29% and 10.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its third quarter 2020 results and recent business performa...

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Alexander Denner, Ph.D., to its Board of Directors, effective November 9, 2020. Dr. De...

Zacks Investment Research - 4 months ago

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time...

Zacks Investment Research - 4 months ago

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that data from IW-3718-302, one of Ironwood’s two identical Phase III t...

Seeking Alpha - 5 months ago

A catalyst is expected for Ironwood, in that it expects an IDMC decision for its phase 3 study IW-3718-302 using IW-3718 to treat patients with refractory GERD Q4 2020.

The Motley Fool - 5 months ago

These stocks hold tremendous potential despite a low price.

Other stocks mentioned: NOK, ZNGA
InvestorPlace - 5 months ago

The novel coronavirus is weighing on the market, but these four biotech stocks can survive. Here's what you need to know to profit now.

Other stocks mentioned: IBB, XBI, XLV
Zacks Investment Research - 5 months ago

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Business Wire - 6 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: 2020 Wells Fargo Virtual He...

Zacks Investment Research - 6 months ago

Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Seeking Alpha - 6 months ago

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Peter Ingram on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 6 months ago

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.

Zacks Investment Research - 6 months ago

Ironwood (IRWD) delivered earnings and revenue surprises of 100.00% and 6.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2020 results and recent business perform...

Zacks Investment Research - 7 months ago

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2020 investor update conference call and webcast at 8:30 a.m.

Business Wire - 7 months ago

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a leading GI-focused healthcare company, today announced that it has reached alignment with the U.S.

Zacks Investment Research - 8 months ago

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 8 months ago

Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Investment Research - 9 months ago

Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.

Zacks Investment Research - 9 months ago

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.

Seeking Alpha - 9 months ago

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Peter Ingram on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Ironwood (IRWD) delivered earnings and revenue surprises of -63.64% and -7.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 11 months ago

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

About IRWD

Ironwood Pharmaceuticals, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for t... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 3, 2010
CEO
Mark Mallon
Employees
232
Stock Exchange
NASDAQ
Ticker Symbol
IRWD
Full Company Profile

Financial Performance

In 2020, IRWD's revenue was $389.52 million, a decrease of -9.08% compared to the previous year's $428.41 million. Earnings were $106.18 million, an increase of 393.73%.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for IRWD stock is "Hold." The 12-month stock price forecast is 11.00, which is an increase of 15.00% from the latest price.

Price Target
$11.00
(15.00% upside)
Analyst Consensus: Hold